

## REMARKS

Applicant submits these Remarks and the sequence list, disk, and related information pursuant to the Examiner's Sequence Rule Letter (Paper 4).

Submitted herewith is the "Sequence Listing" identifiers amendment to the disclosure, wherein reference is made to the sequence by use of assigned identifier (37 CFR 1.821(d)); a substitute "Sequence Listing" computer readable form copy and substitute paper copy (37 CFR 1.821(e) and 1.824); and the required statement that the paper and computer readable copies are the same and include no new matter (37 CFR 1.821(g)).


In view of the above amendments and remarks, it is respectfully submitted that all grounds of objection to nucleotide sequence and/or amino acid sequence disclosures have been addressed. It is believed that the case is now in condition for examination and same is respectfully requested.

Authorization is given to charge payment of any additional fees required, or credit any overpayment, to Deposit Acct. 13-4213.

Respectfully submitted,

Dated: March 28, 2003

By:

  
Stephen A. Slusher, Reg. No. 43,924  
Direct line: (505) 998-6130

PEACOCK, MYERS & ADAMS, P.C.  
Attorneys for Applicant(s)  
P.O. BOX 26927  
Albuquerque, New Mexico 87125-6927  
Telephone: (505) 998-1500  
Facsimile: (505) 243-2542  
**Customer No. 005179**

File: 70024-9902  
[G:\Mike\PATENT\Palatin-Rhomed\MELANOCORTIN METALLO\OA SEQ.Notice To Comply.doc]